Bolest jetre i ishodi među hospitaliziranim pacijentima COVID-19 - sistematski pregled i meta-analiza.
Annals of hepatology
Sažetak istraživanja
Uvod i ciljevi Pandemija bolesti korona virusa 2019. (COVID-19) bila je globalni izazov. U epidemiji teškog akutnog respiratornog sindroma (SARS) 60% pacijenata imalo je oštećenje jetre, a zbog filogenetskih sličnosti virusa pretpostavlja se da je COVID-19 povezan s akutnim oštećenjem jetre. U ovoj meta-analizi, cilj nam je proučiti pojavu i povezanost ozljede jetre, komorbidnih bolesti jetre i povišenih enzima jetre u hospitalizacijama potvrđenim COVID-19 s ishodima. Materijali i metode Podaci iz opservacijskih studija koje opisuju komorbidnu kroničnu bolest jetre, akutnu ozljedu jetre, povišene nivoe aspartat aminotransferaze (AST), alanin aminotransferaze (ALT) i ishode hospitaliziranih pacijenata COVID-19 od 1. decembra 2019. do 30. juna 2020. godine. Izvučen je prema vodiču PRISMA. Neželjeni ishodi su definisani kao prijem u jedinicu intenzivne nege (ICU), zasićenost kiseonikom
Rezultati Uključene su 24 studije sa 12.882 potvrđena pacijenta sa COVID-19. Ukupna prevalencija CM-CLD bila je 2,6%, COVID-19-ALI je bila 26,5%, povišeni AST je bio 41,1%, a povišeni ALT je bio 29,1%. CM-CLD nije imao značajnu povezanost sa lošim ishodima (zbirni OR: 0,96; 95% CI: 0,71-1,29; p=0,78). COVID-19-ALI (1,68;1,04-2,70; p=0,03), povišeni AST (2,98; 2,35-3,77; p
Zaključak Naša meta-analiza sugerira da su akutna ozljeda jetre i povišeni enzimi jetre bili značajno povezani sa COVID-19 kod pacijenata koji bi procijenili promjenu nivoa biološke težine pacijenata. ishodi COVID-19 i uzroci oštećenja jetre tokom infekcije COVID-19.
Prikaži originalni naslov i sažetak na engleskom
Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis.
Introduction and objectives The coronavirus disease 2019 (COVID-19) pandemic has been a challenge globally. In severe acute respiratory syndrome (SARS) epidemic 60% of patients had hepatic injury, due to phylogenetic similarities of the viruses it is assumed that COVID-19 is associated with acute liver injury. In this meta-analysis, we aim to study the occurrence and association of liver injury, comorbid liver disease and elevated liver enzymes in COVID-19 confirmed hospitalizations with outcomes. Materials and methods Data from observational studies describing comorbid chronic liver disease, acute liver injury, elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) levels and outcomes of COVID-19 hospitalized patients from December 1, 2019, to June 30, 2020 was extracted following PRISMA guidelines. Adverse outcomes were defined as admission to intensive care unit (ICU), oxygen saturation
Results 24 studies with 12,882 confirmed COVID-19 patients were included. Overall prevalence of CM-CLD was 2.6%, COVID-19-ALI was 26.5%, elevated AST was 41.1% and elevated ALT was 29.1%. CM-CLD had no significant association with poor outcomes (pooled OR: 0.96; 95% CI: 0.71-1.29; p=0.78). COVID-19-ALI (1.68;1.04-2.70; p=0.03), elevated AST (2.98; 2.35-3.77; p
Conclusion Our meta-analysis suggests that acute liver injury and elevated liver enzymes were significantly associated with COVID-19 severity. Future studies should evaluate changing levels of biomarkers amongst liver disease patients to predict poor outcomes of COVID-19 and causes of liver injury during COVID-19 infection.
Izvorni podaci
- DOI
- 10.1016/j.aohep.2020.10.001
- PMID
- 33075578
- PMCID
- PMC7566821
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom